The flurry of changes to the PARPi indications can cause considerable confusion in clinical practice. It may be difficult for health care professionals to keep track of the emerging data and understand how to apply it to patient care. It is important that health care professionals, including pharmacists, are able to educate their patients on the risks vs. benefits of these agents to help empower them to make informed decisions regarding their treatment.

Learn about the results of recent trials, updates to NCCN Guideline recommendations, and common supportive care needs, so that you can provide optimal management for patients with metastatic prostate cancer.

Advances in pharmacogenomics are widespread in the treatment of cancer. The ongoing research in pharmacogenomics has played a vital role in the diagnosis and treatment of oncologic disease states. It is imperative for the interprofessional oncology care team to have a strong understanding of pharmacogenomics and the ability to correctly apply the standard of care for their patients.

This program will provide expert insights on the current recommendations of care for patients with breast cancer and include the latest clinical research updates to assist clinicians in formulating breast cancer management strategies.

With expanding treatment options, clinicians should understand important criteria used in selecting optimal first- and subsequent-line therapies for individuals with metastatic breast cancer. It is important for clinicians to stay up-to-date with the available treatment options to integrate new evidence-based data into their clinical practice, and being familiar with the toxicity profiles is important to optimize patient outcomes.

Health care providers need to know about the recent updates to the NCCN Guidelines for Non-Small Cell Lung Cancer to provide the best care for their patients with NSCLC, including adverse reactions that may occur with use of the new neoadjuvant and adjuvant systemic therapy regimens.

Due to the rapidly changing treatment landscape, clinicians in the community who treat advanced ovarian cancer may not be aware of new data. In order to optimize clinical outcomes, it is crucial for clinicians to be educated on this topic to ensure that they select the most appropriate treatment options for their patients with ovarian cancer.

The management of cervical cancer specific to histology, stage, and setting has changed tremendously and a review of new/latest data is important and helpful for the practitioners in treatment decision-making. Clinicians can benefit from continued education on comparing treatment options to best manage different histological types of cervical cancer.

The landscape of targeted therapy continues to rapidly evolve, and pharmacists play an integral role on the interprofessional health care team. It is important for pharmacists to be aware of new therapy recommendations in order to provide support by monitoring for drug interactions and adverse drug reactions, understanding the toxicities associated with these agents, and providing patient education.

The treatment landscape for renal cell carcinoma (RCC) is rapidly evolving as new data continue to emerge for novel therapy options. As new immune checkpoint inhibitor (ICI)-based combinations continue to be developed, it is critical for clinicians to recognize and effectively manage immune-related adverse events associated with the ICIs in RCC to ensure maximum benefits from the treatment.